ARTICLE
9 March 2016

Mintz Levin BNA Article Discusses Medicare Overpayment Rule's Implications For Compliance And Enforcement

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
The article describes several key aspects of the Overpayment Rule, identifies open questions, and discusses the Overpayment Rule's implications for compliance as well as health care fraud enforcement.
United States Food, Drugs, Healthcare, Life Sciences

Expanding on our recent discussion of CMS's long-awaited Final Rule governing the return of Medicare Part A and Part B overpayments ("Overpayment Rule"), my colleague Larry Freedman and I published an article in BNA's Medicare Report entitled The Medicare Overpayment Rule: Implications for Compliance and Health Care Enforcement. The article describes several key aspects of the Overpayment Rule, identifies open questions, and discusses the Overpayment Rule's implications for compliance as well as health care fraud enforcement.  In addition, we identify a number of steps that providers and suppliers can take to comply with, and demonstrate compliance with, the Overpayment Rule.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More